Please login to the form below
SMA
This page shows the latest SMA news and features for those working in and with pharma, biotech and healthcare.
Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
Animation. SMA: Race against time by Havas Life Medicom for Novartis Gene Therapies. ... Behavioural Science (NEW). SMA: Race against time by Havas Life Medicom for Novartis Gene Therapies.
Latest news
-
New data shows benefits for presymptomatic SMA patients treated with Zolgensma
Zolgensma was initially approved in 2019 for the treatment of SMA, launching with a list price of $2.125m. ... Since then, Zolgensma has been in competition with Biogen’s SMA drug Spinraza, approved in 2016, and Roche’s newly approved oral therapy
-
Biogen reports new data backing long-term benefit of Spinraza
Biogen has revealed new data for its spinal muscular atrophy (SMA) treatment Spinraza, showing long-term benefit and new insights into the development of a higher dose of the treatment. ... Typically, impaired swallowing is expected for SMA patients with
-
First NHS patient treated with Novartis’ SMA gene therapy Zolgensma
The NHS has treated the first patient with Zolgensma, Novartis’ spinal muscular atrophy (SMA) gene therapy. ... Children born with SMA type 1 typically have a life expectancy of around two years.
-
EU authorises Roche’s spinal muscular atrophy treatment Evrysdi
First SMA treatment approved in the EU that can be taken at home. ... SMA living in the EU,” said Levi Garraway, chief medical officer and head of global product development at Roche.
-
Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA
Children born with SMA type 1 typically have a life expectancy of around two years. ... SMA is a rare genetic disease that causes paralysis, muscle weakness and progressive loss of movement.
New data shows benefits for presymptomatic SMA patients treated with Zolgensma
Biogen reports new data backing long-term benefit of Spinraza
EU authorises Roche’s spinal muscular atrophy treatment Evrysdi
More from news
Approximately 20 fully matching, plus 60 partially matching documents found.
Latest Intelligence
-
The changing nature of approvals – what does the future hold?
Vision for the future. As we look forward, sustainability will continue to influence company strategies, particularly given that some new drugs, such as Zolgensma for spinal muscular atrophy (SMA), cost US$2m
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
the genetic defect underlying spinal muscular atrophy (SMA). ... In the third quarter of 2018, AveXis filed Zolgensma for approval in the US, EU and Japan for the treatment of SMA type I.
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Bluebird is not the only company likely to break through this 1m barrier in 2019 – Novartis’ SMA gene therapy Zolgensma is also on the cusp of approval in the US.
-
Drug launches to watch in 2019
The next step in this process is the launch of Zolgensma (AveXis) – the gene therapy for spinal muscular atrophy (SMA) which is now filed with the FDA and EMA, and is ... The company argues that current ten- year costs of caring for SMA type 1 patients
-
No incentive for a cure
And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to the health of motor
The changing nature of approvals – what does the future hold?
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Drug launches to watch in 2019
No incentive for a cure
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Warp Drive Bio names Gregory Verdine as CEO
He has also served as a global consultant for Roche, scientific adviser to Vertex and Ariad, and currently sits on the boards of the US National Cancer Institute and the SMA
Warp Drive Bio names Gregory Verdine as CEO
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Article: Market access in Brazil
All eyes on Spinraza. Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil? ... In April 2019, Brazilian Health Minister Luiz Henrique
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- WHO to test three more potential COVID-19 treatments
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA green lights study of phage-based drug for resistant infections
- First oral antiviral drug for COVID-19 reviewed by Health Canada
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
